全球動物炭疽疫苗市場規模（按產品、應用、分銷管道、區域範圍和預測）

動物炭疽疫苗市場規模及預測

2024 年獸用炭疽疫苗市場規模價值 91.4 億美元，預計到 2032 年將達到 158.3 億美元，預測期內（2026-2032 年）的複合年成長率為 10.6%。

炭疽疫苗產業規模的擴大歸因於研發活動投資的增加、新進業者的加入、產品創新、技術突破、有效的資源配置，以及競爭對手之間為擴大地域和基本客群加劇的競爭。在不久的將來，政府政策和獎勵、有利的法律​​法規預計將推動炭疽疫苗市場的成長。可支配收入的增加將提高消費者的消費能力，這將有助於炭疽疫苗市場的發展。全球炭疽疫苗市場報告對市場進行了全面的評估。它全面分析了關鍵細分市場、趨勢、市場促進因素、限制因素、競爭格局以及在市場中發揮關鍵作用的因素。

推動全球動物炭疽疫苗市場的因素

獸用炭疽疫苗市場的促進因素受多種因素影響，包括：

• 炭疽菌發病率不斷上升：炭疽菌在牲畜和野生動物群體中爆發的頻率在許多地區仍然令人擔憂。因此，需要製定和實施有效的疫苗接種計劃，以防止炭疽病在牲畜中傳播，保護人類和牲畜的健康。
• 政府措施：政府機構和獸醫部門經常實施疫苗接種計劃，以控制和預防炭疽病疫情。政府在疫苗生產、採購和研發方面的投入推動了獸醫行業對炭疽疫苗的需求。
• 不斷擴張的畜牧業：隨著世界人口的成長，對肉類、乳品和皮革等動物衍生產品的需求也隨之成長。畜牧業的擴張增加了對炭疽菌疫苗的需求，以保護動物免受疾病爆發的侵害，並維持穩定安全的食品供應鏈。
• 知識與教育：獸醫專業人員和畜牧生產者對炭疽菌感染風險的認知不斷提高，有助於推動積極的疫苗接種計劃。由於進行了宣傳工作，強調了疫苗接種在控制炭疽菌疫情的價值，市場規模不斷擴大。
• 技術發展：生物技術和疫苗配方的進步使得開發更安全、更有效的炭疽菌疫苗成為可能。佐劑和創新的給藥方法增強了免疫力，提高了疫苗效力，從而提高了獸醫的疫苗接種率。
• 全球化與貿易：隨著全球牛及牲畜產品貿易量的不斷成長，人們越來越重視疾病的防治，以遵守法規並維持貿易的連續性。炭疽菌疫苗接種計劃對於滿足這些要求並增加市場需求至關重要。
• 疫情防治：炭疽菌是一種生物性危害，在某些地緣政治環境下可能會被人為釋放。各國政府和獸醫機構採購炭疽菌疫苗，作為應對生物恐怖主義風險和保護公眾健康的防控措施的一部分。

限制全球動物炭疽疫苗市場的因素

多種因素可能對動物炭疽疫苗市場造成限制或挑戰。這些因素包括：

• 某些領域的知識有限：有關炭疽菌和疫苗接種價值的知識可能有限，特別是在基礎設施和資源有限的較貧窮國家，這可能會阻礙炭疽菌疫苗的廣泛採用並限制某些地區的市場擴張。
• 監管障礙：動物疫苗的法規核准成本高且耗時。安全性、有效性和品管方面的監管力度加大，可能會使小型疫苗開發商難以進入市場，從而限制競爭和創新。
• 疫苗分發和儲存挑戰：炭疽菌疫苗通常需要特殊的儲存條件，例如冷藏，才能維持其有效性。在沒有低溫運輸基礎設施的地區，確保疫苗的妥善儲存和分發在後勤方面具有挑戰性，這可能會影響疫苗的有效性和可用性。
• 低風險認知：畜牧生產者和獸醫專業人員可能認為，在炭疽病疫情罕見或不規則的地區，感染炭疽菌的可能性很小。這可能會導致自滿情緒，並減少對炭疽菌疫苗的需求，尤其是在炭疽病不太常見的情況下。
• 成本問題：農民接種炭疽疫苗的決定可能會受到疫苗相關成本的影響，包括疫苗成本、疫苗供應成本和獸醫服務成本。在財政狀況不佳或優先事項相互衝突的地區，成本效益的考量可能會阻礙炭疽疫苗的普及。
• 保護效力和持續時間：儘管疫苗技術不斷進步，但炭疽疫苗的保護效力和持續時間仍存在疑問。加強劑量的需求以及疫苗效力的差異性可能會影響疫苗的接種率以及疫苗在市場上的普遍普及度。
• 有效的生物安全措施：除了疫苗接種計畫外，預防牛炭疽菌疫情也至關重要。不良的生物安全措施，例如胴體處理不當或檢疫通訊協定不完善，可能會削弱疫苗宣傳活動的有效性。

目錄

第1章動物炭疽疫苗全球市場介紹

• 市場概覽
• 研究範圍
• 先決條件

第2章執行摘要

第3章：已驗證的市場研究調查方法

• 資料探勘
• 驗證
• 第一手資料
• 資料來源列表

第4章動物炭疽疫苗全球市場展望

• 概述
• 市場動態
  • 驅動程式
  • 限制因素
  • 機會
• 波特五力模型
• 價值鏈分析

5. 全球動物性炭疽疫苗市場（按產品）

• 概述
• 無細胞PA疫苗
• 活病毒疫苗

6. 全球動物性炭疽疫苗市場（依應用）

• 概述
• 對於動物
• 對人類來說

7. 全球動物炭疽疫苗市場（依分銷管道）

• 概述
• 醫院藥房
• 零售藥局
• 其他

8. 全球動物性炭疽疫苗市場（按地區）

• 概述
• 北美洲
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲
  • 德國
  • 英國
  • 法國
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 其他亞太地區
• 世界其他地區
  • 拉丁美洲
  • 中東和非洲

9. 全球動物性炭疽疫苗市場競爭格局

• 概述
• 各公司市場排名
• 主要發展策略

第10章 公司簡介

• Ceva Sante Animale
• Bayer Sanidad Animal
• Central Veterinary Control and Research Institute
• Agrovet
• Colorado Serum Company
• Empresa Colombiana De Productos Veterinarios SA
• Biogenesis Bago SA
• Indian Immunologicals Limited
• Botswana Vaccine Institute
• Centro Diagnostico Veterinario

第11章 公司簡介 附錄

• 相關調查

Veterinary Anthrax Vaccines Market Size And Forecast

Veterinary Anthrax Vaccines Market size was valued at USD 9.14 Billion in 2024 and is projected to reach USD 15.83 Billion by 2032, growing at a CAGR of 10.6% during the forecasted period 2026 to 2032.

The increase in the size of the anthrax vaccines industry can be attributed to rising investments in R&D activities, the entry of new players, product innovation, technological breakthroughs, effective resource allocation, and growing competition among business rivals to expand its regional and customer base. Government policies and incentives, as well as favorable legislation, are expected to drive the growth of the Veterinary Anthrax Vaccines Market in the near future. Customers' spending power will expand as their disposable income rises, contributing to the market profits for anthrax vaccinations. The Global Veterinary Anthrax Vaccines Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Veterinary Anthrax Vaccines Market Drivers

The market drivers for the Veterinary Anthrax Vaccines Market can be influenced by various factors. These may include:

• Rising Anthrax Incidences: In many areas, there is still concern over the frequency of anthrax in livestock and wildlife populations. This makes it necessary to create and implement efficient vaccination programmes in order to prevent the disease from spreading among animals and protect the health of both humans and animals.
• Government Initiatives: To manage and prevent anthrax outbreaks, vaccination programmes are frequently implemented by government agencies and veterinary authorities. Government investments in vaccine production, procurement, and research and development are what fuel the veterinary industry's demand for anthrax vaccinations.
• Expanding Livestock Industry: As the world's population rises, so does the need for goods generated from animals, like meat, milk, and leather. The necessity for anthrax vaccinations to safeguard animal populations against disease outbreaks and maintain a stable and secure food supply chain is increased by the expansion of the livestock industry.
• Knowledge and Education: Proactive immunisation programmes are encouraged by veterinary professionals and livestock farmers' heightened knowledge of the dangers of anthrax infection. The market is growing as a result of education initiatives emphasising the value of immunisation in halting anthrax outbreaks.
• Technological Developments: The development of safer and more effective anthrax vaccinations has been made possible by advances in biotechnology and vaccine formulation methods. Adjuvants and innovative delivery methods extend immunity and improve vaccine efficacy, which increases vaccination rates among veterinarians.
• Globalisation and Trade: In order to comply with regulations and maintain trade continuity, there is a greater emphasis on disease prevention and control as global traffic in cattle and animal products grows. Programmes for immunisation against anthrax are essential for fulfilling these conditions and increasing market demand.
• Preparedness for Outbreaks: Anthrax is still a biological hazard that might be intentionally released in specific geopolitical situations. Vaccinations against anthrax are purchased by governments and veterinary agencies as part of their readiness measures to counter bioterrorism risks and protect public health.

Global Veterinary Anthrax Vaccines Market Restraints

Several factors can act as restraints or challenges for the Veterinary Anthrax Vaccines Market. These may include:

• Limited Knowledge in Some Areas: There may not be enough knowledge about anthrax and the value of vaccination in some areas, especially in poor nations with little infrastructure and resources. This may prevent the spread of anthrax vaccinations and restrict market expansion in certain regions.
• Regulatory Obstacles: Veterinary vaccination regulatory clearances can be expensive and time-consuming. Stricter safety, efficacy, and quality control regulations could make it difficult for smaller vaccine developers to enter the market, which would limit competition and innovation.
• Difficulties with Vaccine Distribution and Storage: To preserve effectiveness, anthrax vaccinations frequently need particular storage settings, such as refrigeration. It can be logistically difficult to ensure appropriate vaccine storage and delivery in areas without cold chain infrastructure, which can affect vaccination efficacy and accessibility.
• Perceived Low Risk: Livestock farmers and veterinary experts may believe that there is little chance of contracting anthrax infection in areas where anthrax outbreaks are uncommon or irregular. This may cause people to become complacent and decrease the demand for anthrax vaccinations, especially when the disease is not as common.
• Cost Issues: Farmers' decisions on vaccination against anthrax may be influenced by costs associated with vaccination, including as the cost of vaccines, vaccination supplies, and veterinarian services. In areas where finances are scarce or priorities conflict, the universal acceptance of the anthrax immunisation may be hindered by its perceived cost-effectiveness.
• Efficacy and Duration of protection: Although vaccine technology has advanced, questions may still remain regarding the effectiveness and longevity of protection offered by anthrax vaccinations. The necessity for booster doses and variations in vaccine efficacy may have an effect on vaccination rates as well as the vaccine's general popularity in the market.
• Effective biosecurity measures: are crucial in preventing anthrax outbreaks in cattle herds, in addition to vaccination programmes. The efficacy of immunisation campaigns may be compromised by inadequate biosecurity measures, such as improper corpse disposal and inadequate quarantine protocols.

Global Veterinary Anthrax Vaccines Market: Segmentation Analysis

The Global Veterinary Anthrax Vaccines Market is Segmented on the basis of Product, Application, Distribution Channel, and Geography.

Veterinary Anthrax Vaccines Market, By Product

• Cell Free PA Vaccines
• Live Attenuated Vaccine

Based on Product, the market is segmented into Cell Free PA Vaccines and Live Attenuated Vaccine. The live vaccines category is expected to increase rapidly throughout the projected period. The live vaccination comprises spores from Bacillus anthracis attenuated strains, which are used to treat anthrax illness. Anthrax is produced by a big bacterium, and the major reason for anthrax immunization is the danger of inhalation infection. All animal vaccinations are live vaccines, and their use for human consumption necessitates a withholding period prior to slaughter.

Veterinary Anthrax Vaccines Market, By Application

• Animal Use
• Human Use

Based on Application, the market is segmented into Animal Use and Human Use. For the forecasted period, the animal usage sector is expected to lead the segment by application. Animals receive a large number of anthrax vaccinations. Anthrax is largely a herbivore disease. In veterinary medicine, a live unencapsulated version of B. anthracis and strain stern has been utilized to protect animals.

Veterinary Anthrax Vaccines Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies

Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Others. Hospital pharmacies have dominated the market and are predicted to rise at a high rate throughout the forecasted period. The hospital pharmacies sector market share has been driven by a series of patients arriving at a hospital emergency department and anthrax vaccinations, which are usually offered in hospital pharmacies. Anthrax vaccinations are not communicable from person to person; nonetheless, typical hospital cleanliness measures must be followed for the therapy, which may only be administered in hospitals.

Veterinary Anthrax Vaccines Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world
• On the basis of Geography, the Global Veterinary Anthrax Vaccines Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. The North American area led the worldwide Veterinary Anthrax Vaccines Market, whereas the Asia Pacific is a fast-rising region. North America dominates the market as a result of government attempts to prevent the spread of anthrax and the existence of several ongoing programs under organizations such as HHS-CDC, BARDA, ASPR, NIAID, and the FDA that are supporting market growth. Asia Pacific is a rapidly rising region as R&D funding increases. Furthermore, the presence of advanced healthcare infrastructure in Japan, as well as broad vaccine manufacturing facilities, is propelling the market growth.

Key Players

The "Global Veterinary Anthrax Vaccines Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Ceva Sante Animale, Bayer Sanidad Animal, Central Veterinary Control and Research Institute, Agrovet, Colorado Serum Company, Empresa Colombiana De Productos Veterinarios S.A., Biogenesis Bago SA, Indian Immunologicals Limited, Botswana Vaccine Institute, and Centro Diagnostico Veterinario.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

• In August 2020, Elusys Therapeutics Inc. (Elusys) received Health Canada clearance for Anthim (obiltoxaximab for injection), a monoclonal antibody (mAb) anthrax antitoxin for the treatment of anthrax inhalation. It can be used to treat post-exposure prophylaxis in both adults and children.
• In August 2020, Dr. Jamie Benn Felix and the Cook Wildlife Lab team from Texas A&M University College of Veterinary Medicine & Biomedical Sciences performed pilot research for the first oral anthrax vaccination for cattle (CVMBS).

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL VETERINARY ANTHRAX VACCINES MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL VETERINARY ANTHRAX VACCINES MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL VETERINARY ANTHRAX VACCINES MARKET, BY PRODUCT

• 5.1 Overview
• 5.2 Cell Free PA Vaccines
• 5.3 Live Attenuated Vaccines

6 GLOBAL VETERINARY ANTHRAX VACCINES MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Animal Use
• 6.3 Human Use

7 GLOBAL VETERINARY ANTHRAX VACCINES MARKET, BY DISTRIBUTION CHANNEL

• 7.1 Overview
• 7.2 Hospital Pharmacies
• 7.3 Retail Pharmacies
• 7.4 Others

8 GLOBAL VETERINARY ANTHRAX VACCINES MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East and Africa

9 GLOBAL VETERINARY ANTHRAX VACCINES MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Ceva Sante Animale
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Bayer Sanidad Animal
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Central Veterinary Control and Research Institute
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Agrovet
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Colorado Serum Company
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Empresa Colombiana De Productos Veterinarios S.A.
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Biogenesis Bago SA
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Indian Immunologicals Limited
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Botswana Vaccine Institute
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 Centro Diagnostico Veterinario
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 Appendix

• 11.1 Related Research